|
T-cell–inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Cellid; Celltrion; Ipsen; MSD Oncology; Novartis |
|
Research Funding - Bristol-Myers Squibb; MSD Oncology |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bayer; Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Novant Health |
Travel, Accommodations, Expenses - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Biogen; Celgene; CVS Health; Emergent BioSolutions; Exelixis; Gilead Sciences; Intuitive Surgical; Ions Pharmaceuticals; Johnson & Johnson; Merck; Pfizer; United Health Group |
Patents, Royalties, Other Intellectual Property - Patents issued and pending (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme |
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme |